Santhera Pharmaceuticals said that it has signed an exclusive distribution agreement with GENESIS Pharma for AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy in 20 markets in Central and Eastern Europe.
The company noted that the collaboration aims to address unmet medical needs by allowing GENESIS Pharma to commercialize AGAMREE in Greece, Cyprus, Malta, Romania, Bulgaria, Slovenia, Croatia, Poland, Czech Republic, Hungary, Slovakia, Lithuania, Latvia, Estonia, Serbia, North Macedonia, Bosnia & Herzegovina, Montenegro, Albania, and Kosovo.
The European Commission approved AGAMREE for the treatment of DMD, in patients 4 years of age and older, in December 2023.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.